YM BioSciences Inc.

YM BioSciences Inc.

YM BioSciences Inc. is a cancer drug development company. It licenses research products from academic institutions and other biotechnology companies which it then develops. Its clinical development portfolio includes four different anti-cancer compounds in a number of formulations targeting seven different tumours or stages of cancer.

Drugs in development include tesmilifene, a small molecule chemopotentiator in a pivotal Phase III trial in metastatic and recurrent breast cancer. Tesmilifene has successfully completed an international Phase III trial in metastatic and recurrent breast cancer and a US and Canadian trial in hormone-refractory prostate cancer. The portfolio also includes a humanized monoclonal antibody targeting the EGF receptor that has completed a Phase II trial in Canada and a GnRH anti-cancer vaccine in a Phase I/II clinical trial for hormone-sensitive early-stage prostate cancer. The EGFr MAb has been accorded Orphan Drug designation in Europe and the USA for glioma.

Company Details

Year Established: 1994

Number of Employees: 15

Company Information

David Allan
Title: Chairman
Area of Responsibility: Management Executive
Telephone: (905) 629-9761
Fax: (905) 629-4959
Email: Click Here

C Mcewen
Title: Investor Relations
Telephone: (905) 629-9761
Fax: (905) 629-4959
Email: Click Here

Products

Theracim Hr3

Norelin Tm
Anti-GnRH anti-cancer vaccine that would target most sex-hormone driven cancers including breast, prostate, uterine fibroids and endometriosis.

Tesmilifene *reg.
Small molecule chemopotentiator for all known classes of current chemotherapies in cancer.

Services